Interferon beta-1a sc at 25 years: a mainstay in the treatment of multiple sclerosis over the period of one generation
Introduction Interferon beta (IFN beta) preparations are an established group of drugs used
for immunomodulation in patients with multiple sclerosis (MS). Subcutaneously (sc) applied …
for immunomodulation in patients with multiple sclerosis (MS). Subcutaneously (sc) applied …
Economic burden of multiple sclerosis in the United States: A systematic literature review
M Schauf, H Chinthapatla, S Dimri, E Li… - Journal of Managed Care …, 2023 - jmcp.org
BACKGROUND: Multiple sclerosis (MS) is chronic progressive disease that poses a
significant economic burden to patients and health care systems in the United States. We …
significant economic burden to patients and health care systems in the United States. We …
[HTML][HTML] Real-world use of cladribine tablets (completion rates and treatment persistence) in patients with multiple sclerosis in England: The CLARENCE study
W Brownlee, A Amin, L Ashton, A Herbert - Multiple Sclerosis and Related …, 2023 - Elsevier
Background Treatment with cladribine tablets, a high-efficacy disease-modifying therapy
(DMT), has been available in England since 2017 for patients with highly active relapsing …
(DMT), has been available in England since 2017 for patients with highly active relapsing …
[HTML][HTML] Treatment patterns by race and ethnicity in newly diagnosed persons with multiple sclerosis
CK Geiger, D Sheinson, TM To, D Jones… - Drugs-Real World …, 2023 - Springer
Abstract Background Non-Hispanic Black and Hispanic persons with MS (pwMS) are more
likely to experience rapid disease progression and severe disability than non-Hispanic …
likely to experience rapid disease progression and severe disability than non-Hispanic …
[HTML][HTML] Beliefs about Medicines and the Level of Intentional Non-Adherence to Treatment among Patients with Multiple Sclerosis Treated with First-Line Drugs
A Kołtuniuk, J Chojdak-Łukasiewicz - Journal of Clinical Medicine, 2023 - mdpi.com
Introduction: Multiple sclerosis (MS) is a chronic inflammatory, demyelinating and
neurodegenerative disease of the central nervous system. MS has no curable disease but …
neurodegenerative disease of the central nervous system. MS has no curable disease but …
[HTML][HTML] The Clinical and Economic Impact of Employees Who Are Care Partners of Patients with Multiple Sclerosis by Disease Severity
B Hendin, RA Brook, IA Beren, N Kleinman… - Journal of Health …, 2023 - ncbi.nlm.nih.gov
Background: Research on employee care partners of patients with multiple sclerosis (MS) is
limited. Objectives: The clinical and economic impact on employee care partners was …
limited. Objectives: The clinical and economic impact on employee care partners was …
Impact of adherence to disease modifying therapies on long-term clinical and economic outcomes in multiple sclerosis: A claims analysis of real-world data
L Amezcua, T Livingston, B Hayward, J Zhou… - Multiple Sclerosis and …, 2023 - Elsevier
Background Multiple sclerosis (MS) is a chronic neurodegenerative inflammatory disease
that requires long-term commitment to treatment for optimal outcomes. A variety of disease …
that requires long-term commitment to treatment for optimal outcomes. A variety of disease …
Medication adherence to disease-modifying therapies among a cohort of Jordanian patients with relapsing-remitting multiple sclerosis: a multicentre cross-sectional …
MS Al-Keilani, BA Almomani - International Journal of Pharmacy …, 2023 - academic.oup.com
Objectives To evaluate medication adherence to oral and parenteral disease-modifying
therapies (DMTs) and to explore factors associated with medication non-adherence in …
therapies (DMTs) and to explore factors associated with medication non-adherence in …
Discontinuation of Disease-Modifying Therapies and Health Outcomes in Midlife Patients with Multiple Sclerosis in the United States
Y Qian - 2023 - search.proquest.com
Multiple sclerosis (MS) is an incurable autoimmune disease that causes neurologic
disability, affecting nearly one million individuals in the United States. Disease-modifying …
disability, affecting nearly one million individuals in the United States. Disease-modifying …
Adherence and persistence to self-administered disease-modifying therapies in patients with multiple sclerosis: A multisite analysis
AD Zuckerman, J DeClercq, D Simonson… - Multiple Sclerosis and …, 2023 - Elsevier
Background Though there are several disease-modifying therapy (DMT) options for patients
with multiple sclerosis (MS), treatment outcomes rely on patient adherence and persistence …
with multiple sclerosis (MS), treatment outcomes rely on patient adherence and persistence …